Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

The Royal Divorce. Gilead Rallied Not Plummeted

June 29, 2016 0

The Royal Divorce On Sunday, the next day after the announcement of the British referendum’s results, …

Ignoring Incyte’s Successive Good News Will Fail to Mislead Investors

June 27, 2016 0

GRAFT VERSUS HOST DISEASE (GVHD) INCYTE (INCY) HAS SEVERAL GOOD NEWS. As a matter of fact, …

Le CompaGnon Part 2

June 23, 2016 0

Le CompaGnon Part 2 Wednesday June 22, 2016 From the American Society of Clinical Oncology (ASCO) …

The Biotech Sector Evolution in the News

June 22, 2016 0

Innoviva (INVA) and GlaxoSmithKline plc (GSK) announced positive results from the pivotal Phase 3 FULFIL study …

Paratek Antibiotic Omadacycline Meets Primary Endpoint in Resistant Infection

June 20, 2016 0

Paratek Pharmaceuticals (PRTK) announced positive results from Phase 3 registration study comparing its once-daily, broad spectrum …

Ariad Pharmaceuticals Submits Early NDA for the Approval of Brigatinib. See Also: More News from Ariad

June 17, 2016 0

ARIAD Pharmaceuticals (ARIA) announced the initiation of a New Drug Application (NDA) submission for brigatinib, the …

Great News for Celator That Might Be Great News for Jazz Pharmaceuticals

June 16, 2016 0

CELATOR PHARMACEUTICALS Good News That Might Go to JAZZ Pharmaceuticals Celator Pharmaceuticals (CPXX): At the European …

SPARK Therapeutics History Foretells Its Triumph in Gene Therapy

June 16, 2016 0

SPARK Spark (NASDAQ: ONCE) is on its way to get an FDA approval of its first …

Le CompaGnon Part 1

June 14, 2016 0

Le CompaGnon Part 1 TUESDAY June 14, 2016 The Eternal Market Games Unfortunately, the fabrication and …

Good News for Agenus and for Global Blood Therapeutics

June 10, 2016 0

Agenus (AGEN) announced that a lead product candidate is selected under its license and research collaboration …

Prohost Letter #396

June 6, 2016 0

Prohost Letter #396 CELEBRATING MEMORIAL DAY - Wish you celebrated the Memorial Day. Memorial Day’s purpose was …

At ASCO: Exelixis Has Great News for Cobimetyx on RCC

June 6, 2016 0

Additional data from pivotal METEOR trial underscore clinically meaningful benefit of Exelixis’ (EXEL) drug Cabometyx™ for …

Theravance Biopharma and Mylan COPD Product is Speeding Towards Approval

June 3, 2016 0

Enrollment has been completed in all the three ongoing clinical trials comprising the firm’s Phase 3 …

Biomarin Decision Might Add More Stress Than Put Pressure on the FDA to Approve Sarepta Drug

June 2, 2016 0

Biomarin Pharmaceutical’s (BMRN) decision to withdraw its DMD drug Kyndrisa™ (drisapersen) Marketing Authorization Application (MAA) from …

IONIS Stock Selloff: Has GSK Abandoned the Wagon or Jumped Out of the Train? See Also: Osteoporosis

May 27, 2016 0

Ionis Pharmaceuticals (IONS) stock plummeted when GlaxoSmithKline (GSK) stopped pursuing a late stage trial of Ionis-TTR …

Great News for Innoviva and COPD Patients

May 25, 2016 0

GlaxoSmithKline and Innoviva: The COPD inhaler Relvar® Ellipta® (known as Brio Ellipta in the United States) …

Exelixis: Results Demonstrate the Potential of Cabozantinib to Become the Gold Standard First Line Treatment for Advanced RCC

May 23, 2016 0

Yes, indeed, the good news has come from the randomized CABOSUN phase 2 trial with Exelixis’ …

Accelerated FDA Approvals of Immunotherapy Treatments Are Accelerating

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

The Royal Divorce. Gilead Rallied Not Plummeted

Ignoring Incyte’s Successive Good News Will Fail to Mislead Investors

Le CompaGnon Part 2

The Biotech Sector Evolution in the News

Paratek Antibiotic Omadacycline Meets Primary Endpoint in Resistant Infection

Ariad Pharmaceuticals Submits Early NDA for the Approval of Brigatinib. See Also: More News from Ariad

Great News for Celator That Might Be Great News for Jazz Pharmaceuticals

SPARK Therapeutics History Foretells Its Triumph in Gene Therapy

Le CompaGnon Part 1

Good News for Agenus and for Global Blood Therapeutics

Prohost Letter #396

At ASCO: Exelixis Has Great News for Cobimetyx on RCC

Theravance Biopharma and Mylan COPD Product is Speeding Towards Approval

Biomarin Decision Might Add More Stress Than Put Pressure on the FDA to Approve Sarepta Drug

IONIS Stock Selloff: Has GSK Abandoned the Wagon or Jumped Out of the Train? See Also: Osteoporosis

Great News for Innoviva and COPD Patients

Exelixis: Results Demonstrate the Potential of Cabozantinib to Become the Gold Standard First Line Treatment for Advanced RCC

Accelerated FDA Approvals of Immunotherapy Treatments Are Accelerating

Portola: Solving the Huge Problem of the New Anticoagulants

Biogen: A Fruitful Collaboration in Gene Therapy. A Small Gene Therapy Firm That You Should Know